Drug recall · February 22, 2017
Glipizide extended-release tablets recall
Why: Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4
- Lots / codes
Lot #: 3134201, 3134202, Exp. 06/30/17; 3134319, Exp. 05/31/17; 3135246, Exp. 07/31/17; 3135247, 3136781, Exp. 08/31/17; 3136782, Exp. 09/30/17; 3136903, 3136904, Exp.10/31/17; 3138250, Exp. 07/31/17; 3138968, Exp. 08/31/17; 3140000, Exp. 09/30/17
- Quantity
- 499320 units
- Company
- Actavis Inc, Parsippany, NJ
- Distribution
- Nationwide in US
- Initiated
- January 30, 2017 · Voluntary: Firm initiated
- Classified
- February 15, 2017
- Reported
- February 22, 2017
- Ended
- March 13, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glipizide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.